Clinical Research Directory

For Part I of the study: Inclusion Criteria: * Diagnosis of HHT by the Curaçao criteria * Several epistaxis/week * Anaemia * COVID-19 vaccination or positive COVID-19 antibody test * Patient has given written informed consent to participate in Part I Exclusion Criteria: * Type 1 diabetes or uncontrolled type II diabetes (insulin or non-insulin dependent) * Active COVID-19 infection * active uncontrolled infection or known to be serologically positive for HIV, Hep B, Hep C infection * Recent procedures on nasal telangiectases (\<6 weeks) * Requiring therapeutic anticoagulation * Use of drugs with anti-angiogenic properties in the past 8 weeks * laboratory abnormalities Fort Part II of the study: Inclusion Criteria: * Completion of Part I of the study * All adverse events or serious adverse events occuring during Part I of the study have resolved * Patient has given written informed consent to participate in Part II Exclusion Criteria: \- Same as in Part I.